TABLE 2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow Versus Broad Next-generation Sequencing Panels

Yiqing Zhao,Anastasios Dimou,Zachary C. Fogarty,Jun Jiang,Hongfang Liu,William B. Wong,Chen Wang

DOI: https://doi.org/10.1158/2767-9764.25145256

2024-01-01

Abstract:Time to test return (turnaround time) for large panel, medium panel, and single-gene genomic tests

What problem does this paper attempt to address?

TABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow Versus Broad Next-generation Sequencing Panels

Yiqing Zhao,Anastasios Dimou,Zachary C. Fogarty,Jun Jiang,Hongfang Liu,William Wong,Chen Wang

DOI: https://doi.org/10.1158/2767-9764.25145259.v1

2024-01-01

Abstract:Demographic characteristics of patients
Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow Versus Broad Next-generation Sequencing Panels.

Yiqing Zhao,Anastasios Dimou,Zachary C. Fogarty,Jun Jiang,Hongfang Liu,William B. Wong,Chen Wang

DOI: https://doi.org/10.1158/2767-9764.crc-23-0190

2024-01-01

Cancer Research Communications

Abstract:Advances in genetic technology have led to the increasing use of genomic panels in precision oncology practice, with panels ranging from a couple to hundreds of genes. However, the clinical utilization and utility of oncology genomic panels, especially among vulnerable populations, is unclear. We examined the association of panel size with socioeconomic status and clinical trial matching. We retrospectively identified 9,886 eligible adult subjects in the Mayo Clinic Health System who underwent genomic testing between January 1, 2016 and June 30, 2020. Patient data were retrieved from structured and unstructured data sources of institutional collections, including cancer registries, clinical data warehouses, and clinical notes. Socioeconomic surrogates were approximated using the Area Deprivation Index (ADI) corresponding to primary residence addresses. Logistic regression was performed to analyze relationships between ADI or rural/urban status and (i) use of genomic test by panel size; (ii) clinical trial matching status. Compared with patients from the most affluent areas, patients had a lower odds of receiving a panel test (vs. a single-gene test) if from areas of higher socioeconomic deprivation [OR (95% confidence interval (CI): 0.71 (0.61-0.83), P < 0.01] or a rural area [OR (95% CI): 0.85 (0.76-0.96), P < 0.01]. Patients in areas of higher socioeconomic deprivation were less likely to be matched to clinical trials if receiving medium panel tests [(OR) (95% CI): 0.69 (0.49-0.97), P = 0.03]; however, there was no difference among patients receiving large panel tests (P > 0.05) and rural patients were almost 2x greater odds of being matched if receiving a large panel test [(OR) (95% CI): 1.76 (1.21-2.55), P < 0.01].
Abstract 6474: Real-world assessment of turn-around time for actionable variant testing in NSCLC in the community setting

Brittany D'Alessio,Adam Stephen,Colin Cochran,Cole Hager,Zachariah Velasco,Amanda Weaver,Leisa Jackson,Janice Riley,Alisa Tubbs,Gary A. Pestano

DOI: https://doi.org/10.1158/1538-7445.am2024-6474

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Introduction: Rapid turnaround times (TAT) is a key parameter when evaluating the performance of cell free (cf) nucleic acid testing in clinical oncology practice. The purpose of this study was to evaluate the impact of the real-world factors on TAT for actionable variants in NSCLC, detected using commercially available molecular diagnostic tests. These test services are run in a single, centralized laboratory site and utilized primarily by practices in the community across the United States. Methods: In this study, de-identified reference data was reviewed for a ddPCR test that evaluates hotspot mutations including Single Nucleotide Variants (SNV), Insertions and Deletions (INDEL), and gene fusions. The NGS panel additionally tests for Copy Number Amplification (CNA) mutations. Specimen processing was initiated when the specimen was entered into the Laboratory Information System (LIS) and ended when the test result was ready for release. The turnaround time evaluation excluded holidays, and weekends unless the start or end-point occurred on a non-business day. Results: In total, 35,441 specimen results were analyzed. Specimens were typically received in the laboratory within 24 hours of being shipped (88% in 24 hours). Tests by ddPCR included 30,490 (86%) results, while NGS testing accounted for 4,951 (14%) of results. The average analytic lab processing TAT for the ddPCR and NGS test ranged between 2 and 3 days (ddPCR median = 24.5 hours; NGS panel median = 69.7 hours). When no information was missing on the specimen test request form, the turn-around time for the ddPCR tests averaged 30.2 hours and NGS panel averaged 66.2 hours. The percentage of missing or inaccurate information was similar when test requests were initially received. The largest impact factor impacting initiation of specimen processing was information related annotation of the stage of cancer, followed by demographic information related to patient and specimen identifiers. Conclusion: The focus on rapid turnaround times from specimen collection to results released is critical in oncology. Site and patient information, shipping methods, technologies and workflows used in the laboratory are all part of the test process and impact the release of potentially actionable results. Our study has highlighted that rapid turnaround of results is highly feasible for molecular tests being sent out from community practices across the US to a centralized reference laboratory. Specifically, actionable variant results related to NSCLC were successfully detected in the laboratory and were ready for delivery in 2 to 3 days. Automated methods for parsing the information necessary for test requests and delivery will continue to be important in maintaining rapid test result turnaround times. Citation Format: Brittany D'Alessio, Adam Stephen, Colin Cochran, Cole Hager, Zachariah Velasco, Amanda Weaver, Leisa Jackson, Janice Riley, Alisa Tubbs, Gary A. Pestano. Real-world assessment of turn-around time for actionable variant testing in NSCLC in the community setting [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6474.

oncology
Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing

Yuan Xue,Arunkanth Ankala,William R. Wilcox,Madhuri R. Hegde

DOI: https://doi.org/10.1038/gim.2014.122

IF: 8.864

2015-06-01

Genetics in Medicine

Abstract:Next-generation sequencing is changing the paradigm of clinical genetic testing. Today there are numerous molecular tests available, including single-gene tests, gene panels, and exome sequencing or genome sequencing. As a result, ordering physicians face the conundrum of selecting the best diagnostic tool for their patients with genetic conditions. Single-gene testing is often most appropriate for conditions with distinctive clinical features and minimal locus heterogeneity. Next-generation sequencing–based gene panel testing, which can be complemented with array comparative genomic hybridization and other ancillary methods, provides a comprehensive and feasible approach for heterogeneous disorders. Exome sequencing and genome sequencing have the advantage of being unbiased regarding what set of genes is analyzed, enabling parallel interrogation of most of the genes in the human genome. However, current limitations of next-generation sequencing technology and our variant interpretation capabilities caution us against offering exome sequencing or genome sequencing as either stand-alone or first-choice diagnostic approaches. A growing interest in personalized medicine calls for the application of genome sequencing in clinical diagnostics, but major challenges must be addressed before its full potential can be realized. Here, we propose a testing algorithm to help clinicians opt for the most appropriate molecular diagnostic tool for each scenario.Genet Med17 6, 444–451.

genetics & heredity
Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use

Zonggao Shi,Jacqueline Lopez,William Kalliney,Bobbie Sutton,Joyce Simpson,Kevin Maggert,Sheng Liu,Jun Wan,M. Sharon Stack

DOI: https://doi.org/10.1371/journal.pone.0266914

IF: 3.7

2022-04-21

PLoS ONE

Abstract:Purpose The demand for high-throughput genetic profiling of somatic mutations in cancer tissues is growing. We sought to establish a targeted next generation sequencing (NGS) panel test for clinical oncology practice. Methods Customized probes were designed to capture exonic regions of 141 genes selected for the panel, which was aimed for the detection of clinically actionable genetic variations in cancer, including KRAS , NRAS , BRAF , ALK , ROS1 , KIT and EGFR . The size of entire targeted regions is 0.8 Mb. Library preparation used NEBNext Ultra II FS kit coupled with target enrichment. Paired-end sequencing was run on Illumina NextSeq 500 at a read length of 150 nt. A bioinformatics workflow focusing on single nucleotide variant and short insertions and deletions (SNV/indel) discovery was established using open source, in-house and commercial software tools. Standard reference DNA samples were used in testing the sensitivity and precision and limit of detection in variant calling. Results The general performance of the panel was observed in pilot runs. Average total reads per sample ranged from 30 million to 48 million, 73% ~82% unique reads. All runs had more than 99% average mapping rate. Mean target coverage ranged from 727x to 879x. Depth of coverage at 50x or more reached 87% of targeted region and 60% of targeted region received 500x or more coverage depth. Using OncoSpan HD827 DNA, which bears 144 variants (SNV/indel) from 80 genes that are within the targeted region on the panel, our somatic variant calling pipeline reached 97% sensitivity and 100% precision respectively, with near 48 million reads. High concordance with orthogonal approaches in variant detection was further verified with 7 cancer cell lines and 45 clinical specimens. Conclusion We developed a NGS panel with a focus on clinically actionable gene mutations and validated the performance in library construction, sequencing and variant calling. High concordance with reference materials and orthogonal mutation detection was observed.

multidisciplinary sciences
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

Binsheng Gong,Dan Li,Rebecca Kusko,Natalia Novoradovskaya,Yifan Zhang,Shangzi Wang,Carlos Pabón-Peña,Zhihong Zhang,Kevin Lai,Wanshi Cai,Jennifer S. LoCoco,Eric Lader,Todd A. Richmond,Vinay K. Mittal,Liang-Chun Liu,Donald J. Johann,James C. Willey,Pierre R. Bushel,Ying Yu,Chang Xu,Guangchun Chen,Daniel Burgess,Simon Cawley,Kristina Giorda,Nathan Haseley,Fujun Qiu,Katherine Wilkins,Hanane Arib,Claire Attwooll,Kevin Babson,Longlong Bao,Wenjun Bao,Anne Bergstrom Lucas,Hunter Best,Ambica Bhandari,Halil Bisgin,James Blackburn,Thomas M. Blomquist,Lisa Boardman,Blake Burgher,Daniel J. Butler,Chia-Jung Chang,Alka Chaubey,Tao Chen,Marco Chierici,Christopher R. Chin,Devin Close,Jeffrey Conroy,Jessica Cooley Coleman,Daniel J. Craig,Erin Crawford,Angela del Pozo,Ira W. Deveson,Daniel Duncan,Agda Karina Eterovic,Xiaohui Fan,Jonathan Foox,Cesare Furlanello,Abhisek Ghosal,Sean Glenn,Meijian Guan,Christine Haag,Xinyi Hang,Scott Happe,Brittany Hennigan,Jennifer Hipp,Huixiao Hong,Kyle Horvath,Jianhong Hu,Li-Yuan Hung,Mirna Jarosz,Jennifer Kerkhof,Benjamin Kipp,David Philip Kreil,Paweł Łabaj,Pablo Lapunzina,Peng Li,Quan-Zhen Li,Weihua Li,Zhiguang Li,Yu Liang,Shaoqing Liu,Zhichao Liu,Charles Ma,Narasimha Marella,Rubén Martín-Arenas,Dalila B. Megherbi,Qingchang Meng,Piotr A. Mieczkowski,Tom Morrison,Donna Muzny,Baitang Ning,Barbara L. Parsons,Cloud P. Paweletz,Mehdi Pirooznia,Wubin Qu,Amelia Raymond,Paul Rindler,Rebecca Ringler,Bekim Sadikovic,Andreas Scherer,Egbert Schulze,Robert Sebra,Rita Shaknovich,Qiang Shi,Tieliu Shi,Juan Carlos Silla-Castro,Melissa Smith,Mario Solís López,Ping Song,Daniel Stetson,Maya Strahl,Alan Stuart,Julianna Supplee,Philippe Szankasi,Haowen Tan,Lin-ya Tang,Yonghui Tao,Shraddha Thakkar,Danielle Thierry-Mieg,Jean Thierry-Mieg,Venkat J. Thodima,David Thomas,Boris Tichý,Nikola Tom,Elena Vallespin Garcia,Suman Verma,Kimbley Walker,Charles Wang,Junwen Wang,Yexun Wang,Zhining Wen,Valtteri Wirta,Leihong Wu,Chunlin Xiao,Wenzhong Xiao,Shibei Xu,Mary Yang,Jianming Ying,Shun H. Yip,Guangliang Zhang,Sa Zhang,Meiru Zhao,Yuanting Zheng,Xiaoyan Zhou,Christopher E. Mason,Timothy Mercer,Weida Tong,Leming Shi,Wendell Jones,Joshua Xu

DOI: https://doi.org/10.1186/s13059-021-02315-0

IF: 17.906

2021-04-16

Genome Biology

Abstract:Abstract Background Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence Quality Control project phase2 (SEQC2) effort, we perform a cross-platform multi-lab evaluation of eight Pan-Cancer panels to assess best practices for oncopanel sequencing. Results All panels demonstrate high sensitivity across targeted high-confidence coding regions and variant types for the variants previously verified to have variant allele frequency (VAF) in the 5–20% range. Sensitivity is reduced by utilizing VAF thresholds due to inherent variability in VAF measurements. Enforcing a VAF threshold for reporting has a positive impact on reducing false positive calls. Importantly, the false positive rate is found to be significantly higher outside the high-confidence coding regions, resulting in lower reproducibility. Thus, region restriction and VAF thresholds lead to low relative technical variability in estimating promising biomarkers and tumor mutational burden. Conclusion This comprehensive study provides actionable guidelines for oncopanel sequencing and clear evidence that supports a simplified approach to assess the analytical performance of oncopanels. It will facilitate the rapid implementation, validation, and quality control of oncopanels in clinical use.

genetics & heredity,biotechnology & applied microbiology
Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting

Gregory A Vidal,Neha Jain,Aaron Fisher,Daniel Sheinson,Katherine T Lofgren,Esprit Ma,Elaine Yu,Leah Comment,Rebecca Miksad,Murat Sincan,Richard Lewis Martin,Richard Zuniga,Davey Daniel,Gregory A. Vidal,Katherine T. Lofgren

DOI: https://doi.org/10.1200/op.23.00253

2024-01-09

JCO Oncology Practice

Abstract:PURPOSE Racial/ethnic inequities in next-generation sequencing (NGS) were examined for patients with advanced non–small-cell lung cancer (aNSCLC) at the practice and physician levels to inform policies to improve equitable quality of care. METHODS This retrospective study used a nationwide electronic health record–derived deidentified database for patients with aNSCLC diagnosed between April 2018 and March 2022 in the community setting. Timely NGS was an NGS result between initial diagnosis and ≤60 days after advanced diagnosis. We studied how inequities were driven by (1) non-Latinx Black (Black) and Latinx patient under-representation at high testing practices versus (2) Black and Latinx patients being tested at lower rates than non-Latinx White (White) patients, even at the same practice. We defined these two concepts as across inequity and within inequity, respectively, with total inequity as their summation. Mean percentage point inequities were estimated using a Bayesian approach. RESULTS A total of 12,045 patients (9,981 White; 1,528 Black; 536 Latinx) met study criteria. At the practice level, versus White patients, the mean percentage point difference in NGS testing total inequity was 7.49 for Black and 8.26 for Latinx. Within- and across-practice inequities contributed to total inequity in NGS testing for Black (48% v 52%) and Latinx patients (60% v 40%). At the physician level, versus White patients, the mean percentage point difference in total inequity was 7.73 for Black and 8.81 for Latinx patients. Within- versus across-physician inequities contributed to total inequity for Black and Latinx patients (77% v 23% and 67% v 33%). CONCLUSION Within-practice, across-practice, and across-physician inequities were main contributors to total inequity in NGS testing, requiring a suite of interventions to effectively address inequities.

oncology
The application of long-read sequencing in clinical settings

Josephine B. Oehler,Helen Wright,Zornitza Stark,Andrew J. Mallett,Ulf Schmitz

DOI: https://doi.org/10.1186/s40246-023-00522-3

2023-08-09

Human Genomics

Abstract:Long-read DNA sequencing technologies have been rapidly evolving in recent years, and their ability to assess large and complex regions of the genome makes them ideal for clinical applications in molecular diagnosis and therapy selection, thereby providing a valuable tool for precision medicine. In the third-generation sequencing duopoly, Oxford Nanopore Technologies and Pacific Biosciences work towards increasing the accuracy, throughput, and portability of long-read sequencing methods while trying to keep costs low. These trades have made long-read sequencing an attractive tool for use in research and clinical settings. This article provides an overview of current clinical applications and limitations of long-read sequencing and explores its potential for point-of-care testing and health care in remote settings.

genetics & heredity
Rural-urban and racial-ethnic differences in awareness of direct-to-consumer genetic testing

Ramzi G. Salloum,Thomas J. George,Natalie Silver,Merry-Jennifer Markham,Jaclyn M. Hall,Yi Guo,Jiang Bian,Elizabeth A. Shenkman

DOI: https://doi.org/10.1186/s12889-018-5190-6

IF: 4.5

2018-02-23

BMC Public Health

Abstract:BackgroundAccess to direct-to-consumer genetic testing services has increased in recent years. However, disparities in knowledge and awareness of these services are not well documented. We examined awareness of genetic testing services by rural/urban and racial/ethnic status.MethodsAnalyses were conducted using pooled cross-sectional data from 4 waves (2011–2014) of the Health Information National Trends Survey (HINTS). Descriptive statistics compared sample characteristics and information sources by rural/urban residence. Logistic regression was used to examine the relationship between geography, racial/ethnic status, and awareness of genetic testing, controlling for sociodemographic characteristics.ResultsOf 13,749 respondents, 16.7% resided in rural areas, 13.8% were Hispanic, and 10.1% were non-Hispanic black. Rural residents were less likely than urban residents to report awareness of genetic testing (OR = 0.74, 95% CI = 0.63–0.87). Compared with non-Hispanic whites, racial/ethnic minorities were less likely to be aware of genetic testing: Hispanic (OR = 0.68, 95% CI = 0.56–0.82); and non-Hispanic black (OR = 0.74, 95% CI = 0.61–0.90).ConclusionsRural-urban and racial-ethnic differences exist in awareness of direct-to-consumer genetic testing. These differences may translate into disparities in the uptake of genetic testing, health behavior change, and disease prevention through precision and personalized medicine.

public, environmental & occupational health
The Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health System

Chetan V. Vakkalagadda,Danielle B. Dressler,Zequn Sun,Joseph Fuchs,Yingzhe Liu,Philip Silberman,Avanthi Ragam,Sheetal Kircher,Jyoti D. Patel,Nisha A. Mohindra

DOI: https://doi.org/10.3390/cancers16213654

2024-10-30

Cancers

Abstract:Purpose: Broad-based molecular testing with next-generation sequencing (NGS) is now the standard of care in advanced non-small cell lung cancer (NSCLC). Two approaches to molecular testing are (1) reflexive testing at pathologic NSCLC confirmation, often using an in-house molecular panel, and (2) send-out testing to private vendors, ordered by a clinician. This study explored the outcomes with reflex versus send-out testing. Methods: A retrospective chart review was conducted of patients diagnosed with de novo stage IV NSCLC in 2019 and 2020 at three hospitals in the same system, one academic hospital (Northwestern Memorial Hospital, or NMH) utilizing reflex, in-house NGS, and two community-based hospitals (Central DuPage Hospital, or CDH, and Delnor, or D) sending out tissue samples for testing. The outcomes assessed were the time from biopsy to results, biopsy to treatment, the incidence of first-line targetable mutations and the use of first-line targeted therapies, and overall survival. Results: In total, 191 patients met the inclusion criteria, 85 at NMH, 106 at CDH + D, and in total, 131 in 2019 and 60 in 2020. The time to results was significantly shorter with reflexive NGS when compared with send-out testing; the time to treatment was also shorter but not statistically significant. At CDH + D, the time to results was significantly shorter with a limited panel than with comprehensive testing, but the time to treatment was similar. NGS testing rates were 95% at NMH and 84.5% at CDH + D (p = 0.009), with 31.0% at NMH receiving 1L targeted therapies versus 20.8% at CDH + D (p = 0.08). In 2019, the median time from biopsy to treatment was 35 days at NMH and 38 days at CDH and Delnor; in 2020, time to treatment was 26 days and 37 days, respectively. Overall survival trended longer in 2020 relative to 2019 independent of site. Conclusion: Reflexive NGS testing is associated with a shorter time to actionable results and higher rates of first-line targetable mutations than send-out testing. In practices with send-out testing, limited panels had slightly faster turnaround times but no difference in time to treatment. If resources allow, reflexive NGS should be considered in healthcare systems for patients with NSCLC.

oncology
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

Emma G Sturgill,Amanda Misch,Rebecca Lachs,Carissa C Jones,Dan Schlauch,Suzanne F Jones,Mythili Shastry,Denise A Yardley,Howard A Burris 3rd,David R Spigel,Erika P Hamilton,Andrew J McKenzie

DOI: https://doi.org/10.1200/PO.20.00469

Abstract:Purpose: Molecular biomarkers informing disease diagnosis, prognosis, and treatment decisions in patients with breast cancer are being uncovered by next-generation sequencing (NGS) technologies. In this study, we survey how NGS is used for patients with breast cancer in real-world settings with a focus on physician behaviors and sequencing results. Methods: We conducted a retrospective analysis of patients with breast cancer who received NGS testing from commercial vendors as part of standard of care from 2014 to 2019. A total of 2,635 NGS reports from 2,316 unique breast cancer patients were assessed. Hormone receptor and human epidermal growth factor receptor 2 statuses were abstracted from patient medical records. Comparative gene amplification and mutation frequencies were analyzed using Pearson's correlation and Lin's concordance statistics. Results: The number of physicians ordering NGS tests for patients with breast cancer increased more than six-fold from 2014 to 2019. Tissue- and plasma-based tests were ordered roughly equally by 2019, with plasma-based testing ordered most frequently in hormone receptor-positive subtypes. Patients with triple-negative breast cancer were most likely to receive NGS testing. Gene amplifications including ERBB2 were detected less frequently in our real-world data set as compared to previous genomic landscape studies, whereas the opposite was true for gene mutations including ESR1. Pathogenic mutations in the PI3K pathway (38.6%) and DNA damage repair pathway (11.0%) were frequently reported. Alterations were also reported across other cellular pathways. Conclusion: Overall, we found that an increasing number of physicians in community settings are adopting NGS in the care of patients with breast cancer. Discrepancies between our real-world NGS data and previous genomic landscape studies are likely owed to the prevalence of plasma-based testing in community oncology clinics, as the reference data were from tissue-based NGS alone.
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency

Wendell Jones,Binsheng Gong,Natalia Novoradovskaya,Dan Li,Rebecca Kusko,Todd A. Richmond,Donald J. Johann,Halil Bisgin,Sayed Mohammad Ebrahim Sahraeian,Pierre R. Bushel,Mehdi Pirooznia,Katherine Wilkins,Marco Chierici,Wenjun Bao,Lee Scott Basehore,Anne Bergstrom Lucas,Daniel Burgess,Daniel J. Butler,Simon Cawley,Chia-Jung Chang,Guangchun Chen,Tao Chen,Yun-Ching Chen,Daniel J. Craig,Angela del Pozo,Jonathan Foox,Margherita Francescatto,Yutao Fu,Cesare Furlanello,Kristina Giorda,Kira P. Grist,Meijian Guan,Yingyi Hao,Scott Happe,Gunjan Hariani,Nathan Haseley,Jeff Jasper,Giuseppe Jurman,David Philip Kreil,Paweł Łabaj,Kevin Lai,Jianying Li,Quan-Zhen Li,Yulong Li,Zhiguang Li,Zhichao Liu,Mario Solís López,Kelci Miclaus,Raymond Miller,Vinay K. Mittal,Marghoob Mohiyuddin,Carlos Pabón-Peña,Barbara L. Parsons,Fujun Qiu,Andreas Scherer,Tieliu Shi,Suzy Stiegelmeyer,Chen Suo,Nikola Tom,Dong Wang,Zhining Wen,Leihong Wu,Wenzhong Xiao,Chang Xu,Ying Yu,Jiyang Zhang,Yifan Zhang,Zhihong Zhang,Yuanting Zheng,Christopher E. Mason,James C. Willey,Weida Tong,Leming Shi,Joshua Xu

DOI: https://doi.org/10.1186/s13059-021-02316-z

IF: 17.906

2021-04-16

Genome Biology

Abstract:Abstract Background Oncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials. Currently, there is a paucity of reliable genomic reference samples having a suitably large number of pre-identified variants for properly assessing oncopanel assay analytical quality and performance. The FDA-led Sequencing and Quality Control Phase 2 (SEQC2) consortium analyze ten diverse cancer cell lines individually and their pool, termed Sample A, to develop a reference sample with suitably large numbers of coding positions with known (variant) positives and negatives for properly evaluating oncopanel analytical performance. Results In reference Sample A, we identify more than 40,000 variants down to 1% allele frequency with more than 25,000 variants having less than 20% allele frequency with 1653 variants in COSMIC-related genes. This is 5–100× more than existing commercially available samples. We also identify an unprecedented number of negative positions in coding regions, allowing statistical rigor in assessing limit-of-detection, sensitivity, and precision. Over 300 loci are randomly selected and independently verified via droplet digital PCR with 100% concordance. Agilent normal reference Sample B can be admixed with Sample A to create new samples with a similar number of known variants at much lower allele frequency than what exists in Sample A natively, including known variants having allele frequency of 0.02%, a range suitable for assessing liquid biopsy panels. Conclusion These new reference samples and their admixtures provide superior capability for performing oncopanel quality control, analytical accuracy, and validation for small to large oncopanels and liquid biopsy assays.

genetics & heredity,biotechnology & applied microbiology
Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test

Anath C Lionel,Gregory Costain,Nasim Monfared,Susan Walker,Miriam S Reuter,S Mohsen Hosseini,Bhooma Thiruvahindrapuram,Daniele Merico,Rebekah Jobling,Thomas Nalpathamkalam,Giovanna Pellecchia,Wilson W L Sung,Zhuozhi Wang,Peter Bikangaga,Cyrus Boelman,Melissa T Carter,Dawn Cordeiro,Cheryl Cytrynbaum,Sharon D Dell,Priya Dhir,James J Dowling,Elise Heon,Stacy Hewson,Linda Hiraki,Michal Inbar-Feigenberg,Regan Klatt,Jonathan Kronick,Ronald M Laxer,Christoph Licht,Heather MacDonald,Saadet Mercimek-Andrews,Roberto Mendoza-Londono,Tino Piscione,Rayfel Schneider,Andreas Schulze,Earl Silverman,Komudi Siriwardena,O Carter Snead,Neal Sondheimer,Joanne Sutherland,Ajoy Vincent,Jonathan D Wasserman,Rosanna Weksberg,Cheryl Shuman,Chris Carew,Michael J Szego,Robin Z Hayeems,Raveen Basran,Dimitri J Stavropoulos,Peter N Ray,Sarah Bowdin,M Stephen Meyn,Ronald D Cohn,Stephen W Scherer,Christian R Marshall,Anath C. Lionel,Miriam S. Reuter,S. Mohsen Hosseini,Wilson W.L. Sung,Melissa T. Carter,Sharon D. Dell,James J. Dowling,Ronald M. Laxer,O. Carter Snead,Jonathan D. Wasserman,Michael J. Szego,Robin Z. Hayeems,Dimitri J. Stavropoulos,Peter N. Ray,M. Stephen Meyn,Ronald D. Cohn,Stephen W. Scherer,Christian R. Marshall

DOI: https://doi.org/10.1038/gim.2017.119

IF: 8.864

2018-04-01

Genetics in Medicine

Abstract:PurposeGenetic testing is an integral diagnostic component of pediatric medicine. Standard of care is often a time-consuming stepwise approach involving chromosomal microarray analysis and targeted gene sequencing panels, which can be costly and inconclusive. Whole-genome sequencing (WGS) provides a comprehensive testing platform that has the potential to streamline genetic assessments, but there are limited comparative data to guide its clinical use.MethodsWe prospectively recruited 103 patients from pediatric non-genetic subspecialty clinics, each with a clinical phenotype suggestive of an underlying genetic disorder, and compared the diagnostic yield and coverage of WGS with those of conventional genetic testing.ResultsWGS identified diagnostic variants in 41% of individuals, representing a significant increase over conventional testing results (24%; P = 0.01). Genes clinically sequenced in the cohort (n = 1,226) were well covered by WGS, with a median exonic coverage of 40 × ±8 × (mean ±SD). All the molecular diagnoses made by conventional methods were captured by WGS. The 18 new diagnoses made with WGS included structural and non-exonic sequence variants not detectable with whole-exome sequencing, and confirmed recent disease associations with the genes PIGG, RNU4ATAC, TRIO, and UNC13A.ConclusionWGS as a primary clinical test provided a higher diagnostic yield than conventional genetic testing in a clinically heterogeneous cohort.

genetics & heredity
Clinical Next Generation Sequencing for Precision Medicine in Cancer

Ling Dong,Wanheng Wang,Alvin Li,Rina Kansal,Yuhan Chen,Hong Chen,Xinmin Li

DOI: https://doi.org/10.2174/1389202915666150511205313

2015-01-01

Current Genomics

Abstract:Rapid adoption of next generation sequencing (NGS) in genomic medicine has been driven by low cost, high throughput sequencing and rapid advances in our understanding of the genetic bases of human diseases. Today, the NGS method has dominated sequencing space in genomic research, and quickly entered clinical practice. Because unique features of NGS perfectly meet the clinical reality (need to do more with less), the NGS technology is becoming a driving force to realize the dream of precision medicine. This article describes the strengths of NGS, NGS panels used in precision medicine, current applications of NGS in cytology, and its challenges and future directions for routine clinical use.
Improving timeliness and equity in germline genetic testing for pancreatic ductal adenocarcinoma patients: A comparative analysis and future strategies.

Xianghui Zou,Baho Sidiqi,Cathy Nguyen,Ellen Chen,Noah D. Kauff,Daniel King

DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.611

IF: 45.3

2024-01-23

Journal of Clinical Oncology

Abstract:611 Background: Germline genetic testing is recommended for patients with pancreatic ductal adenocarcinoma (PDAC). Our previous study identified delays in germline testing for socioeconomically disadvantaged patients. We aimed to compare delays before and after implementing recommendations for same-day germline testing and identify reasons why germline testing was not performed. Methods: Using an IRB-approved protocol, PDAC patients were identified from Jan 2022 to Dec 2022 in our EMR system. Median income was estimated by zip code. Delays were calculated as the difference between diagnosis and germline test date. Social work needs were assessed through EMR review. An in-depth chart review was conducted to identify why tests were not performed. Results: An additional 100 patients were found with tests performed. Compared to our previous 135-patient study with a median delay of 27 days (d) in testing, our recent data showed a median delay of 15d (p=0.0215). In our previous study, 50 out of 135 patients (37%) received testing within two weeks of their PDAC diagnosis, whereas our recent data showed that 49 out of 100 patients (49%) received testing within two weeks (c 2 =3.372, p=0.0663), a 32% relative increase. The negative correlation between median income and delays in testing (r=-0.2578, p=0.0025) found in our previous study no longer existed in our recent analysis (r=0.0419, p=0.6802). Compared to our previous study in underserved minority (UM) patients (African American and Hispanic), our recent data showed a significant decrease in the delays for testing in UM patients (66d vs 19d, p=0.0041). We did not identify a difference in delays for testing between UM and not UM patients in the recent dataset (UM: 19d vs not UM: 15d, p=0.8075). In addition, compared to our previous study in patients with social work (SW) needs, our recent data showed a significant decrease in the delays for patients with SW needs (104d vs 13d, p=0.0004). We did not detect a significant difference between patients with SW needs and without SW needs in our recent data (SW: 13d vs no SW: 15d, p=0.8041). Finally, in our analysis of 87 patients without documented tests, 51 (59%) received care elsewhere, 25 (29%) were never offered tests, 5 (6%) refused tests, and 6 (7%) pursued a palliative approach. Conclusions: Our recent analysis showed a significant decrease in delays of testing, as more patients received prompt testing after PDAC diagnosis. Socioeconomically disadvantaged patients and those with social work needs no longer experienced significant delays in testing. To further mitigate delays, we plan to initiate germline testing during the first visit by providing introductory videos to increase understanding of consent. Furthermore, the substantial number of patients who were not offered tests will raise physician awareness regarding the necessity of offering germline tests.

oncology
Next-generation sequencing in the clinic: Promises and challenges

Jiekun Xuan,Ying Yu,Tao Qing,Lei Guo,Leming Shi

DOI: https://doi.org/10.1016/j.canlet.2012.11.025

IF: 9.756

2013-11-01

Cancer Letters

Abstract:The advent of next generation sequencing (NGS) technologies has revolutionized the field of genomics, enabling fast and cost-effective generation of genome-scale sequence data with exquisite resolution and accuracy. Over the past years, rapid technological advances led by academic institutions and companies have continued to broaden NGS applications from research to the clinic. A recent crop of discoveries have highlighted the medical impact of NGS technologies on Mendelian and complex diseases, particularly cancer. However, the ever-increasing pace of NGS adoption presents enormous challenges in terms of data processing, storage, management and interpretation as well as sequencing quality control, which hinder the translation from sequence data into clinical practice. In this review, we first summarize the technical characteristics and performance of current NGS platforms. We further highlight advances in the applications of NGS technologies towards the development of clinical diagnostics and therapeutics. Common issues in NGS workflows are also discussed to guide the selection of NGS platforms and pipelines for specific research purposes.

oncology
Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study

Lauren R. Desrosiers-Battu,Tao Wang,Jacquelyn Reuther,George Miles,Hongzheng Dai,Eunji Jo,Heidi Russell,Robin Raesz-Martinez,Alva Recinos,Stephanie Gutierrez,Amy Thomas,Emily Berenson,Jessica Corredor,Kimberly Nugent,Rachel Wyatt Castillo,Rebecca Althaus,Rebecca Littlejohn,Shawn Gessay,Gail Tomlinson,Jonathan Gill,Juan Carlos Bernini,Kelly Vallance,Timothy Griffin,Sarah Scollon,Frank Y. Lin,Christine Eng,Shashikant Kulkarni,Susan G. Hilsenbeck,Angshumoy Roy,Amy L. McGuire,D. Williams Parsons,Sharon E. Plon

DOI: https://doi.org/10.1200/po.24.00187

2024-09-01

JCO Precision Oncology

Abstract:PURPOSE To evaluate the relative diagnostic yield of clinical germline genomic tests in a diverse pediatric cancer population. PATIENTS AND METHODS The KidsCanSeq study enrolled pediatric cancer patients across six sites in Texas. Germline analysis included both exome sequencing and a therapy-focused pediatric cancer gene panel. The results were categorized by participants demographics, the presence of pathogenic or likely pathogenic (P/LP) variants, and variants of uncertain significance (VUS) in cancer predisposition genes (CPGs). Pediatric actionable CPGs were defined as those with cancer surveillance recommendations during childhood. RESULTS Cancer P/LP variants were reported by at least one platform in 103 of 578 (17.8%) participants of which 76 were dominant cancer genes (13.1%) with no significant differences by self-described race or Hispanic ethnicity. However, the proportion of participants with VUS was greater in Asian and African American participants ( P = .0029). Diagnostic yield was 16.6% for exome versus 8.5% for panel ( P < .0001) with 42 participants with concordant germline results. Exome-only results included P/LP variants in 30 different CPGs in 54 participants, whereas panel-only results included seven participants with a copy number or structural P/LP variants in CPGs. There was no significant difference in diagnostic yield limited to pediatric actionable CPGs ( P = .6171). CONCLUSION Approximately 18% of a diverse pediatric cancer population had germline diagnostic findings with 50% of P/LP variants reported by only one platform because of CPGs not on the targeted panel and copy number variants (CNVs)/rearrangements not reported by exome. Although diagnostic yields were similar in this diverse population, increases in VUS results were observed in Asian and African American populations. Given the clinical significance of CNVs/rearrangements in this cohort, detection is critical to optimize germline analysis of pediatric cancer populations.

oncology
NGS panels' capture of biomarkers associated with targeted therapies in clinical trials.

John Leonard Fox,Sugganth Daniel,Manavi Abrol

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e13508

IF: 45.3

2024-05-31

Journal of Clinical Oncology

Abstract:e13508 Background: ASCO and NCCN guidelines strongly encourage participation in clinical trials though participation rates remain low. Although up to 60% of trials require biomarker information as a prerequisite to participation, guidelines are silent on biomarker testing to assess eligibility. To help inform policy development, we analyzed commercially available NGS panels to assess the capture rate of the specific gene variants required for targeted therapies in clinical trials. Methods: Publicly available gene variant information on 12 high volume NGS tissue and plasma commercial assays representative of panel size was accessed. The JAX-CKB database was queried to identify genomic prerequisites in active phase I-III clinical trials; mRNA and protein expression biomarkers were excluded. We used unpaired t-testing to compare the ability of large versus small panels to detect variants required for targeted treatments. (Somatic gene variant annotations and related content have been powered by The Jackson Laboratory Clinical Knowledgebase (JAX-CKBTM)). Results: Overall, 185 genes were linked to eligibility for targeted therapies in clinical trials (Table). Large panel assays (>80 genes) had a higher average capture rate compared to smaller panels, (84% vs. 46%, p value < 0.000002). Similarly, capture rates in select cancers were higher in larger panels: lung (85% vs 59%), breast (92% vs 54%), prostate (86% vs 34%), pancreatic (84% vs 54%), colorectal (88% vs 52%). All results were statistically significant (p < 0.05). Smaller panels were more likely to exclude large genes (e.g. BRCA), genome-wide signatures (e.g. TMB), fusions, and copy number variants. Conclusions: NGS-based panels with more than 80 genes had higher capture rates for biomarkers required for clinical trials of targeted therapies. Clinicians searching for all relevant treatment options for patients should include large genomic sequencing panels to maximize identification of potential clinical trial eligibility. Professional societies and policy makers interested in enhancing clinical trial enrollment rates should consider the panel size-related variability in capture rates of genetic variants when developing recommendations. [Table: see text]

oncology
Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing

Binsheng Gong,Dan Li,Paweł P. Łabaj,Bohu Pan,Natalia Novoradovskaya,Danielle Thierry-Mieg,Jean Thierry-Mieg,Guangchun Chen,Anne Bergstrom Lucas,Jennifer S. LoCoco,Todd A. Richmond,Elizabeth Tseng,Rebecca Kusko,Scott Happe,Timothy R. Mercer,Carlos Pabón-Peña,Michael Salmans,Hagen U. Tilgner,Wenzhong Xiao,Donald J. Johann Jr,Wendell Jones,Weida Tong,Christopher E. Mason,David P. Kreil,Joshua Xu

DOI: https://doi.org/10.1038/s41597-024-03741-y

2024-08-18

Scientific Data

Abstract:Next-generation sequencing (NGS) has revolutionized genomic research by enabling high-throughput, cost-effective genome and transcriptome sequencing accelerating personalized medicine for complex diseases, including cancer. Whole genome/transcriptome sequencing (WGS/WTS) provides comprehensive insights, while targeted sequencing is more cost-effective and sensitive. In comparison to short-read sequencing, which still dominates the field due to high speed and cost-effectiveness, long-read sequencing can overcome alignment limitations and better discriminate similar sequences from alternative transcripts or repetitive regions. Hybrid sequencing combines the best strengths of different technologies for a more comprehensive view of genomic/transcriptomic variations. Understanding each technology's strengths and limitations is critical for translating cutting-edge technologies into clinical applications. In this study, we sequenced DNA and RNA libraries of reference samples using various targeted DNA and RNA panels and the whole transcriptome on both short-read and long-read platforms. This study design enables a comprehensive analysis of sequencing technologies, targeting protocols, and library preparation methods. Our expanded profiling landscape establishes a reference point for assessing current sequencing technologies, facilitating informed decision-making in genomic research and precision medicine.

multidisciplinary sciences
Exome and Whole-Genome Sequencing As Clinical Tests: a Transformative Practice in Molecular Diagnostics.

Yongguo Yu,Bai-lin Wu,Jie Wu,Yiping Shen

DOI: https://doi.org/10.1373/clinchem.2012.193128

IF: 12.114

2012-01-01

Clinical Chemistry

Abstract:In the last few years, next-generation sequencing (NGS)5 has revolutionized the approaches by which we interrogate the genetic causes of rare single-gene disorders (1). More recently, NGS has been rapidly moving into the clinical diagnostics arena and transforming the practice of molecular diagnostics testing. Many NGS-based tests for multigene panels are available in clinical laboratories. Now, proof-of-principle studies are demonstrating the feasibility of using exome sequencing for clinical testing (2–4). Dixon-Salazar et al. used exome sequencing to interrogate a cohort of 118 probands with recessive neurodevelopmental disorders and identified disease-causing mutations in 19% of the probands. Importantly, exome sequencing uncovered mutations in 10 probands (8% of the cohort) that altered the initial clinical diagnosis and led in some cases to a change in patient management (2). Calvo et al. tested 42 infants with mitochondrial diseases with the “MitoExome” (mitochondrial DNA plus exons of approximately 1000 nuclear genes) and confirmed that 10 patients (24% of the cohort) had pathogenic mutations. In addition, these investigators identified 2 novel disease-causing genes (3). Need et al. used exome sequencing in family trios to investigate patients with a broad range of phenotypic presentations and reported a 33% diagnostic yield: 4 of 12 patients with apparently causal mutations and 2 additional potentially novel disease-causing genes (4). Although the number of patients tested thus far by whole-exome sequencing (WES) or whole-genome sequencing (WGS) is still small, the data reported in these recent studies have defined the minimal diagnostic yields of such NGS-based clinical tests at their early stage of implementation, thus demonstrating the practicality of NGS-based tests. We anticipate that the clinical utility of NGS-based tests will improve further in the next few years and that more patients will benefit from improved diagnostic accuracy and more-appropriate treatment. Conventional molecular diagnostics tests evaluate a defined …

TABLE 2 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow Versus Broad Next-generation Sequencing Panels

TABLE 1 from Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow Versus Broad Next-generation Sequencing Panels

Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow Versus Broad Next-generation Sequencing Panels.

Abstract 6474: Real-world assessment of turn-around time for actionable variant testing in NSCLC in the community setting

Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing

Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use

Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting

The application of long-read sequencing in clinical settings

Rural-urban and racial-ethnic differences in awareness of direct-to-consumer genetic testing

The Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health System

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency

Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test

Clinical Next Generation Sequencing for Precision Medicine in Cancer

Improving timeliness and equity in germline genetic testing for pancreatic ductal adenocarcinoma patients: A comparative analysis and future strategies.

Next-generation sequencing in the clinic: Promises and challenges

Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study

NGS panels' capture of biomarkers associated with targeted therapies in clinical trials.

Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing

Exome and Whole-Genome Sequencing As Clinical Tests: a Transformative Practice in Molecular Diagnostics.